Ann: ATL1102 DMD Paediatric Investigation Plan submitted to EMA, page-30

Agree Sam, 1102 has very quickly gone from an experimental drug for MS to now, potentially, a block buster solution for inflammation across a wide range of indications, competing head on with Corticosteroids in a 100B+ market. Negotiating the complexities of a deal this size will require an industry champion with unique skill sets and extensive experience in exchange of high value assets, partnership deals and take overs. We are entering into the big league now, we need a strong assertive deal maker on the board to get this over the line.